In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo
Authors
Keywords
-
Journal
Nature Communications
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-11-27
DOI
10.1038/s41467-020-19486-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The promise of mRNA vaccines: a biotech and industrial perspective
- (2020) Nicholas A. C. Jackson et al. npj Vaccines
- Poly(beta-amino ester)s as gene delivery vehicles: challenges and opportunities
- (2020) Johan Karlsson et al. Expert Opinion on Drug Delivery
- Allogeneic CAR T cell therapies for leukemia - R1
- (2019) Waseem Qasim AMERICAN JOURNAL OF HEMATOLOGY
- CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
- (2019) Mohamad Hamieh et al. NATURE
- The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy
- (2019) Jessica B. Foster et al. MOLECULAR THERAPY
- How mRNA therapeutics are entering the monoclonal antibody field
- (2019) Lien Van Hoecke et al. Journal of Translational Medicine
- Manufacturing chimeric antigen receptor T cells: issues and challenges
- (2019) Claire Roddie et al. CYTOTHERAPY
- Taking a "BiTE out of ALL" - Blinautmomab approval for MRD positive ALL
- (2019) Emily Curran et al. BLOOD
- Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma
- (2019) Cesar Sommer et al. MOLECULAR THERAPY
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant
- (2019) Aude G. Chapuis et al. NATURE MEDICINE
- Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
- (2018) Gregory L. Beatty et al. GASTROENTEROLOGY
- T cells grafted with HBV-specific T-cell receptors of high functional avidity achieve functional cure of HBV infection in humanized mice
- (2018) K. Wisskirchen et al. JOURNAL OF HEPATOLOGY
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rapid, Single-Cell Analysis and Discovery of Vectored mRNA Transfection In Vivo with a loxP-Flanked tdTomato Reporter Mouse
- (2018) Kevin J. Kauffman et al. Molecular Therapy-Nucleic Acids
- Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells
- (2018) Pappanaicken R. Kumaresan et al. Frontiers in Immunology
- The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies
- (2018) Maja M. Janas et al. TOXICOLOGIC PATHOLOGY
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- Roadmap and strategy for overcoming infusion reactions to nanomedicines
- (2018) Janos Szebeni et al. Nature Nanotechnology
- Allogeneic CAR-T Cells: More than Ease of Access?
- (2018) Charlotte Graham et al. Cells
- Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection
- (2017) Janine Kah et al. JOURNAL OF CLINICAL INVESTIGATION
- Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells
- (2017) Malika Hale et al. MOLECULAR THERAPY
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
- (2017) Frederick L. Locke et al. MOLECULAR THERAPY
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
- (2017) Tyrel T. Smith et al. Nature Nanotechnology
- N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density
- (2017) Yuri V. Svitkin et al. NUCLEIC ACIDS RESEARCH
- Safety Evaluation of Lipid Nanoparticle–Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey
- (2017) Maja Sedic et al. VETERINARY PATHOLOGY
- Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers
- (2017) H. F. Moffett et al. Nature Communications
- FDA Approves Second CAR T-cell Therapy
- (2017) Cancer Discovery
- Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
- (2017) Giedre Krenciute et al. Cancer Immunology Research
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
- (2016) Chun-Meng Wang et al. CLINICAL CANCER RESEARCH
- T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma
- (2015) Ingunn M. Stromnes et al. CANCER CELL
- T-Cell Therapy: Options for Infectious Diseases: Table 1.
- (2015) Shreemanta K. Parida et al. CLINICAL INFECTIOUS DISEASES
- CAR therapy: the CD19 paradigm
- (2015) Michel Sadelain JOURNAL OF CLINICAL INVESTIGATION
- Dual-Affinity Re-Targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells
- (2015) Julia A.M. Sung et al. JOURNAL OF CLINICAL INVESTIGATION
- Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells
- (2015) Dongmei Fan et al. Journal of Hematology & Oncology
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Are BiTEs the “missing link” in cancer therapy?
- (2015) Carter M Suryadevara et al. OncoImmunology
- Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection
- (2013) T. M. Schmitt et al. BLOOD
- Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines
- (2013) Marina A. Dobrovolskaia et al. JOURNAL OF CONTROLLED RELEASE
- Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells
- (2013) Usanarat Anurathapan et al. MOLECULAR THERAPY
- Tumour heterogeneity and cancer cell plasticity
- (2013) Corbin E. Meacham et al. NATURE
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia
- (2013) Marco L. Davila et al. PLoS One
- Mechanisms of Nanoparticle-Induced Oxidative Stress and Toxicity
- (2013) Amruta Manke et al. Biomed Research International
- Non-viral gene delivery nanoparticles based on Poly(β-amino esters) for treatment of glioblastoma
- (2011) Stephany Y. Tzeng et al. BIOMATERIALS
- Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma
- (2011) Ulrike Gerdemann et al. MOLECULAR THERAPY
- Hepatitis B: The virus and disease
- (2010) T. Jake Liang HEPATOLOGY
- Blood Cytokines as Biomarkers of In Vivo Toxicity in Preclinical Safety Assessment: Considerations for Their Use
- (2010) Jacqueline M. Tarrant TOXICOLOGICAL SCIENCES
- Promising tumor-associated antigens for future prostate cancer therapy
- (2009) Yong Li et al. MEDICINAL RESEARCH REVIEWS
- Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
- (2008) Katalin Karikó et al. MOLECULAR THERAPY
- Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner
- (2008) S. R. Nallagatla et al. RNA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now